The E2F3-Oncomir-1 axis is activated in Wilms' tumor.

Oncomir-1 is an oncogenic cluster of microRNAs (miRNA) located on chromosome 13. Previous in vitro studies showed that it is transcriptionally regulated by the transcription factor E2F3. In this report, we combine expression profiling of both mRNA and miRNAs in Wilms' tumor (WT) samples to provide the first evidence that the E2F3-Oncomir-1 axis, previously identified in cell culture, is deregulated in primary human tumors. Analysis of RNA expression signatures showed that an E2F3 gene signature was activated in all WT samples analyzed, in contrast to other kidney tumors. This finding was validated by immunohistochemistry on the protein level. Expression of E2F3 was lowest in early-stage tumors and highest in metastatic tissue. Expression profiling of miRNAs in WT showed that expression of each measured member of the Oncomir-1 family was highest in WT relative to other kidney tumor subtypes. Quantitative PCR confirmed that these miRNAs were overexpressed in WT relative to normal kidney tissue. These results suggest that the E2F3-Oncomir-1 axis is activated in WT. Our study also shows the utility of integrated genomics combining gene signature analysis with miRNA expression profiling to identify protein-miRNA interactions that are perturbed in disease states.

[1]  Gordon K Smyth,et al.  Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .

[2]  Trevor Hastie,et al.  Gene Expression Programs in Response to Hypoxia: Cell Type Specificity and Prognostic Significance in Human Cancers , 2006, PLoS medicine.

[3]  R. Sandberg,et al.  Assessment of tumor characteristic gene expression in cell lines using a tissue similarity index (TSI). , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[4]  R. Wooster,et al.  Amplification and overexpression of E2F3 in human bladder cancer , 2004, Oncogene.

[5]  Ximing J. Yang,et al.  Gene expression profiling in kidney cancer: combining differential expression and chromosomal and pathway analyses. , 2006, Clinical genitourinary cancer.

[6]  Bin Tean Teh,et al.  MicroRNA profiling of human kidney cancer subtypes. , 2009, International journal of oncology.

[7]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[8]  J. M. Thomson,et al.  Direct Regulation of an Oncogenic Micro-RNA Cluster by E2F Transcription Factors* , 2007, Journal of Biological Chemistry.

[9]  A. Nicholson,et al.  Nuclear overexpression of the E2F3 transcription factor in human lung cancer. , 2006, Lung cancer.

[10]  Rosalind Eeles,et al.  Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome , 2004, Oncogene.

[11]  M. Knowles,et al.  Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification , 2008, Oncogene.

[12]  W. Linehan,et al.  The consequences of chromosomal aneuploidy on gene expression profiles in a cell line model for prostate carcinogenesis. , 2001, Cancer research.

[13]  K. Furge,et al.  Combined genetic and transcriptional profiling of acute myeloid leukemia with normal and complex karyotypes. , 2004, Haematologica.

[14]  K. Furge,et al.  Identification of frequent cytogenetic aberrations in hepatocellular carcinoma using gene-expression microarray data , 2002, Genome Biology.

[15]  R. Myers,et al.  Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data , 2005, Nucleic acids research.

[16]  Ximing J. Yang,et al.  Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma. , 2007, Cancer research.

[17]  Seon-Young Kim,et al.  PAGE: Parametric Analysis of Gene Set Enrichment , 2005, BMC Bioinform..

[18]  林下 陽二.  A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation , 2006 .